Maxime Barat1, Audrey Fohlen2,3,4,5,6, Christophe Cassinotto7,8, Anne Sophie Jannot9,10,11, Raphael Dautry1, Jean-Pierre Pelage2,3,4,5,6, Mourad Boudiaf1, Marc Pocard12,13,14, Clarisse Eveno12,13,14, Bachir Taouli15, Philippe Soyer1,12,13, Anthony Dohan1,12,13,16. 1. Department of Body and Interventional Imaging, Hôpital Lariboisière, Paris, France. 2. CNRS, UMR 6301-ISTCT, CERVOxy, GIP CYCERON, Caen, France. 3. CEA, DSV/I2BM, UMR6301-ISTCT, Caen, France. 4. Normandie Université, France. 5. UNICAEN, UMR6301-ISTCT, Caen, France. 6. CHU de CAEN, Service d'Imagerie Diagnostique et de Radiologie Thérapeutique, Caen, France. 7. Department of Diagnostic and Interventional Imaging, Hôpîtal Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France. 8. INSERM U1053, Université Bordeaux, Bordeaux, France. 9. INSERM-UMRS 1138 Team 22, Cordeliers Research Center, Paris, France. 10. Paris Descartes University, Paris, France. 11. Department of Medical Informatics and Public Health, European George Pompidou Hospital, Paris, France. 12. Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France. 13. UMR CART - INSERM 965, Hôpital Lariboisière, Paris, France. 14. Department of Digestive Surgery, Hôpital Lariboisière, Paris, France. 15. Department of Radiology and Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 16. McGill University Health Center, Department of Radiology, McGill University Health Center, Montreal, QC, Canada.
Abstract
PURPOSE: To assess whether apparent diffusion coefficient (ADC) values at 1 and 3 months after radiofrequency ablation (RFA) may be associated with a favorable response to therapy for hepatocellular carcinoma (HCC) and liver metastases. MATERIALS AND METHODS: Fifty-nine patients with HCC (n = 35) or liver metastases (n = 24) who underwent 1.5T diffusion-weighted magnetic resonance imaging (DWMRI) at 1 and 3 months post-RFA were included. ADC values of patients with local tumor recurrence were compared to those without local recurrence. A subgroup analysis was performed for HCC and metastases. RESULTS: Thirty-eight HCC and 27 metastases were evaluated. The ADC value of HCC at 1 month after RFA was lower in recurrent tumors (0.957 ± 0.229 [SD] × 10-3 mm2 ) compared to tumors with complete response (1.414 ± 0.322 [SD] × 10-3 mm2 /s, P = 0.006). At multivariate analysis, ADC at 1 month was the single independent variable associated with recurrence for HCC (area under the receiver operating characteristic curve = 0.860). No significant association was observed for liver metastases (P = 0.089). CONCLUSION: A low ADC value at 1 month after RFA is associated with an early local recurrence of HCC. This study does not confirm that such association exists for hepatic metastases. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;45:1648-1658.
PURPOSE: To assess whether apparent diffusion coefficient (ADC) values at 1 and 3 months after radiofrequency ablation (RFA) may be associated with a favorable response to therapy for hepatocellular carcinoma (HCC) and liver metastases. MATERIALS AND METHODS: Fifty-nine patients with HCC (n = 35) or liver metastases (n = 24) who underwent 1.5T diffusion-weighted magnetic resonance imaging (DWMRI) at 1 and 3 months post-RFA were included. ADC values of patients with local tumor recurrence were compared to those without local recurrence. A subgroup analysis was performed for HCC and metastases. RESULTS: Thirty-eight HCC and 27 metastases were evaluated. The ADC value of HCC at 1 month after RFA was lower in recurrent tumors (0.957 ± 0.229 [SD] × 10-3 mm2 ) compared to tumors with complete response (1.414 ± 0.322 [SD] × 10-3 mm2 /s, P = 0.006). At multivariate analysis, ADC at 1 month was the single independent variable associated with recurrence for HCC (area under the receiver operating characteristic curve = 0.860). No significant association was observed for liver metastases (P = 0.089). CONCLUSION: A low ADC value at 1 month after RFA is associated with an early local recurrence of HCC. This study does not confirm that such association exists for hepatic metastases. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;45:1648-1658.